Cullinan Therapeutics, Inc. - Common Stock — Cash Flow (NASDAQ:CGEM) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -43.43 M-126.66 M-134.28 M-145.3 M-175.75 M -178.64 M Cash from investing activities -333.77 M248.97 M35.81 M-136.31 M179.99 M 175.6 M Cash from financing activities 268.78 M-25.93 M40.75 M266.19 M1.09 M 1.47 M Free cash flow -43.43 M-126.66 M-134.28 M-145.3 M-175.8 M -178.65 M

News

Will Health Benefits Weakness Drag Elevance's Q1 Earnings?

Stifel raises Cullinan Oncology stock price target on autoimmune progress

Cullinan Therapeutics: Thesis Strengthening For T-Cell Engager Specialist (NASDAQ:CGEM)

Cullinan Therapeutics, Inc. (CGEM) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

TheStreet Pro Analysts Say, “Big Tech Names are Anything But Cheap – Buy These 2 Stocks Instead” - TipRanks.com

Guggenheim initiates Cullinan Oncology stock with Buy rating, $30 target

Cullinan Therapeutics Stock: Cash-Rich Biotech With Multiple Value Drivers (NASDAQ:CGEM)

Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year?

Here's What Could Help Cullinan Therapeutics (CGEM) Maintain Its Recent Price Strength

Cullinan Therapeutics plans data readouts for key autoimmune programs

Cowen reiterates Buy rating on Cullinan Oncology stock after ASH data

Cullinan Therapeutics, Inc. (CGEM) Discusses Initial CLN-049 Results and Development Strategy for AML Applications Transcript